Pharmacological study of a cannabinoid-containing eyedrop formulation in dogs and mice

Publication date: Available online 23 May 2015 Source:Journal of Applied Biomedicine Author(s): Aline Maria Stolf , Daiana Lugarini , Anabel de Oliveira , Adriana Pastre Sereniki , Caroline Capitelli , Douglas Hideki Tanaka , Fabiano Montiani Ferreira , Maria Aparecida Barbato Frazão Vital , Alexandra Acco Cannabinoids have been indicated for the treatment of glaucoma in humans. However, pharmacological studies in other species are lacking. Healthy Beagle dogs were treated with 0.1% cannabinoid eyedrops for 3 or 7 days. Intraocular pressure (IOP) and pupillary diameter (PD) were measured. To evaluate whether the topical cannabinoid formulation affects the motor and central nervous systems, a parallel study was performed. Male Swiss mice received ocular or intraperitoneal (i.p.) cannabinoid solution for 1 day (acute) or 7 days (subacute) and were tested in the open field (OF), elevated plus maze (EPM), open field habituation test (HT), and marble burying test (MBT). The treated dogs exhibited a significant reduction of IOP and PD. Acute i.p. cannabinoid administration reduced locomotion in mice in the OF and increased the number of entries into the open arms of the EPM. Subacute ocular cannabinoid administration increased the time spent on the closed arms and reduced the time spent on the open arms of the EPM. The cannabinoid i.p. and ocular did not exert anxiogenic effects in the MBT. These results indicate that the cannabinoid reduced IOP when used topically, a...

Source: Journal of Applied Biomedicine - May 23, 2015 Category: Biotechnology Source Type: research